A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders

References

• MerrittKMcGuirePEgertonARelationship between Glutamate Dysfunction and Symptoms and Cognitive Function in PsychosisFront Psychiatry2013415124324444
   PubMedGoogle Scholar
• HashimotoKMalchowBFalkaiPSchmittAGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disordersEur Arch Psychiatry Clin Neurosci2013263536737723455590
   PubMed Web of Science ®Google Scholar
• MusazziLTreccaniGMalleiAPopoliMThe action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptorsBiol Psychiatry201373121180118823273725
   PubMed Web of Science ®Google Scholar
• CoyleJTBasuABenneyworthMBaluDKonopaskeGGlutamatergic synaptic dysregulation in schizophrenia: therapeutic implicationsHandb Exp Pharmacol201221326729523027419
   PubMedGoogle Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders5th edWashington, DCAmerican Psychiatric Association2014
   Google Scholar
• LeckmanJFGriceDEBoardmanJSymptoms of obsessive-compulsive disorderAm J Psychiatry199715479119179210740
   PubMed Web of Science ®Google Scholar
• RuscioAMSteinDJChiuWTKesslerRCThe epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey ReplicationMol Psychiatry2010151536318725912
   PubMed Web of Science ®Google Scholar
• HeymanIFombonneESimmonsHFordTMeltzerHGoodmanRPrevalence of obsessive-compulsive disorder in the British nationwide survey of child mental healthBr J Psychiatry200117932432911581112
   PubMed Web of Science ®Google Scholar
• CraskeMGTreanorMConwayCCZbozinekTVervlietBMaximizing exposure therapy: an inhibitory learning approachBehav Res Ther201458102324864005
   PubMed Web of Science ®Google Scholar
• Pediatric OCD Treatment Study (POTS) TeamCognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trialJAMA2004292161969197615507582
   PubMed Web of Science ®Google Scholar
• RosenbergDRKeshavanMSAE Bennett Research Award. Toward a neurodevelopmental model of obsessive – compulsive disorderBiol Psychiatry19984396236409582996
   PubMed Web of Science ®Google Scholar
• LujánRShigemotoRLópez-BenditoGGlutamate and GABA receptor signalling in the developing brainNeuroscience2005130356758015590141
   PubMed Web of Science ®Google Scholar
• MartinLJFurutaABlackstoneCDAMPA receptor protein in developing rat brain: glutamate receptor-1 expression and localization change at regional, cellular, and subcellular levels with maturationNeuroscience19988339179289483574
   PubMed Web of Science ®Google Scholar
• FurutaAMartinLJLaminar segregation of the cortical plate during corticogenesis is accompanied by changes in glutamate receptor expressionJ Neurobiol1999391678010213454
   PubMed Web of Science ®Google Scholar
• SattlerRTymianskiMMolecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell deathMol Neurobiol2001241–310712911831548
   PubMed Web of Science ®Google Scholar
• GradosMASpechtMWSungHMFortuneDGlutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approachExpert Opin Drug Discov20138121515152724147578
   PubMed Web of Science ®Google Scholar
• RosenbergDRMacMasterFPKeshavanMSFitzgeraldKDStewartCMMooreGJDecrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetineJ Am Acad Child Adolesc Psychiatry20003991096110310986805
   PubMed Web of Science ®Google Scholar
• MacMasterFPO’NeillJRosenbergDRBrain imaging in pediatric obsessive-compulsive disorderJ Am Acad Child Adolesc Psychiatry200847111262127218827717
   PubMed Web of Science ®Google Scholar
• ArnoldPDSicardTBurroughsERichterMAKennedyJLGlutamate transporter gene SLC1A1 associated with obsessive-compulsive disorderArch Gen Psychiatry200663776977616818866
   PubMed Web of Science ®Google Scholar
• StewartSEFagernessJAPlatkoJAssociation of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorderAm J Med Genet B Neuropsychiatr Genet2007144B81027103317894418
   PubMed Web of Science ®Google Scholar
• DickelDEVeenstra-VanderWeeleJCoxNJAssociation testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorderArch Gen Psychiatry200663777878516818867
   PubMed Web of Science ®Google Scholar
• ShugartYYWangYSamuelsJFA family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder in 378 familiesAm J Med Genet B Neuropsychiatr Genet2009150B688689219152386
   PubMed Web of Science ®Google Scholar
• StewartSEMayerfeldCArnoldPDMeta-analysis of association between obsessive-compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1Am J Med Genet B Neuropsychiatr Genet2013162B436737923606572
   PubMed Web of Science ®Google Scholar
• ArnoldPDMacmasterFPRichterMAGlutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorderPsychiatry Res2009172213613919324536
   PubMed Web of Science ®Google Scholar
• AlonsoPGratacósMSegalàsCAssociation between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorderJ Psychiatry Neurosci201237427328122433450
   PubMed Web of Science ®Google Scholar
• TükelROzataBOztürkNErtekinBAErtekinEDireskeneliGSThe role of the brain-derived neurotrophic factor SNP rs2883187 in the phenotypic expression of obsessive-compulsive disorderJ Clin Neurosci201421579079324291483
   PubMed Web of Science ®Google Scholar
• MárquezLCamarenaBHernándezSLóyzagaCVargasLNicoliniHAssociation study between BDNF gene variants and Mexican patients with obsessive-compulsive disorderEur Neuropsychopharmacol201323111600160523999029
   PubMed Web of Science ®Google Scholar
• TükelRGürvitHOzataBBrain-derived neurotrophic factor gene Val66Met polymorphism and cognitive function in obsessive-compulsive disorderAm J Med Genet B Neuropsychiatr Genet2012159B785085822911909
   PubMed Web of Science ®Google Scholar
• GreenbergBDZiemannUCorá-LocatelliGAltered cortical excitability in obsessive-compulsive disorderNeurology200054114214710636140
   PubMed Web of Science ®Google Scholar
• PittengerCKrystalJHCoricVGlutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorderNeuroRx200631698116490414
   PubMedGoogle Scholar
• NicolasLBKolbYPrinssenEPA combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressantsEur J Pharmacol20065471–310611516934246
   PubMed Web of Science ®Google Scholar
• ShimazakiTIijimaMChakiSAnxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior testEur J Pharmacol20045011–312112515464070
   PubMed Web of Science ®Google Scholar
• WelchJMLuJRodriguizRMCortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant miceNature2007448715689490017713528
   PubMed Web of Science ®Google Scholar
• ChenMWanYAdeKTingJFengGCalakosNSapap3 deletion anomalously activates short-term endocannabinoid-mediated synaptic plasticityJ Neurosci201131269563957321715621
   PubMed Web of Science ®Google Scholar
• JoelDAvisarAExcessive lever pressing following post-training signal attenuation in rats: a possible animal model of obsessive compulsive disorder?Behav Brain Res20011231778711377731
   PubMed Web of Science ®Google Scholar
• AlbeldaNBar-OnNJoelDThe role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorderPsychopharmacology (Berl)20102101132420238210
   PubMed Web of Science ®Google Scholar
• Alves GalvãoMGRochaCrispinoSantosMAAlves da CunhaAJAmantadine and rimantadine for influenza A in children and the elderlyCochrane Database Syst Rev20081CD00274518254006
   PubMed Web of Science ®Google Scholar
• WilliamsSEAmantadine treatment following traumatic brain injury in childrenBrain Inj200721988588917729042
   PubMed Web of Science ®Google Scholar
• DraytonSJDaviesKSteinbergMLeroiIRosenblattALyketsosCGAmantadine for executive dysfunction syndrome in patients with dementiaPsychosomatics200445320520915123844
   PubMed Web of Science ®Google Scholar
• HubsherGHaiderMOkunMSAmantadine: the journey from fighting flu to treating Parkinson diseaseNeurology201278141096109922474298
   PubMed Web of Science ®Google Scholar
• HosenbocusSChahalRAmantadine: a review of use in child and adolescent psychiatryJ Can Acad Child Adolesc Psychiatry2013221556023390434
   PubMedGoogle Scholar
• NeagoeADDelirium with manic and psychotic features associated with amantadineGen Hosp Psychiatry2013356680.e7e823731892
   PubMed Web of Science ®Google Scholar
• PasquiniMBerardelliIBiondiMAmantadine augmentation for refractory obsessive-compulsive disorder: a case reportJ Clin Psychopharmacol2010301858620075660
   PubMed Web of Science ®Google Scholar
• StryjerRBudnikDEbertTAmantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label studyClin Neuropharmacol2014373798124824662
   PubMed Web of Science ®Google Scholar
• MyskiwJCIzquierdoIFuriniCRModulation of the extinction of fear learningBrain Res Bull2014105616924742526
   PubMed Web of Science ®Google Scholar
• NorbergMMKrystalJHTolinDFA meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapyBiol Psychiatry200863121118112618313643
   PubMed Web of Science ®Google Scholar
• LeeHKimJJAmygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned ratsJ Neurosci19981820844484549763487
   PubMed Web of Science ®Google Scholar
• HofmannSGPollackMHOttoMWAugmentation treatment of psychotherapy for anxiety disorders with D-cycloserineCNS Drug Rev2006123–420821717227287
   PubMedGoogle Scholar
• KushnerMGKimSWDonahueCD-cycloserine augmented exposure therapy for obsessive-compulsive disorderBiol Psychiatry200762883583817588545
   PubMed Web of Science ®Google Scholar
• WilhelmSBuhlmannUTolinDFAugmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorderAm J Psychiatry20081653335341 quiz 40918245177
   PubMed Web of Science ®Google Scholar
• StorchEAMerloLJBengtsonMD-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorderInt Clin Psychopharmacol200722423023717519647
   PubMed Web of Science ®Google Scholar
• RodriguesHFigueiraILopesADoes D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysisPLoS One201497e9351924991926
   PubMed Web of Science ®Google Scholar
• HernandesMSTronconeLRGlycine as a neurotransmitter in the forebrain: a short reviewJ Neural Transm2009116121551156019826900
   PubMed Web of Science ®Google Scholar
• ClementsJDWestbrookGLActivation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptorNeuron1991746056131681832
   PubMed Web of Science ®Google Scholar
• LabrieVRoderJCThe involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophreniaNeurosci Biobehav Rev201034335137219695284
   PubMed Web of Science ®Google Scholar
• GreenbergWMBenedictMMDoerferJAdjunctive glycine in the treatment of obsessive-compulsive disorder in adultsJ Psychiatr Res200943666467019046587
   PubMed Web of Science ®Google Scholar
• KrystalJHKarperLPSeibylJPSubanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responsesArch Gen Psychiatry19945131992148122957
   PubMed Web of Science ®Google Scholar
• BermanRMCappielloAAnandAAntidepressant effects of ketamine in depressed patientsBiol Psychiatry200047435135410686270
   PubMed Web of Science ®Google Scholar
• CaddyCGiaroliGWhiteTPShergillSSTracyDKKetamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacyTher Adv Psychopharmacol201442759924688759
   PubMedGoogle Scholar
• RodriguezCIKegelesLSFloodPSimpsonHBRapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorderJ Clin Psychiatry201172456756921527129
   PubMed Web of Science ®Google Scholar
• BlochMHWasylinkSLanderos-WeisenbergerAEffects of ketamine in treatment-refractory obsessive-compulsive disorderBiol Psychiatry2012721196497022784486
   PubMed Web of Science ®Google Scholar
• RodriguezCIKegelesLSLevinsonARandomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-conceptNeuropsychopharmacology201338122475248323783065
   PubMed Web of Science ®Google Scholar
• XieXHaganRMCellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorderNeuropsychobiology19983831191309778599
   PubMed Web of Science ®Google Scholar
• CunninghamMOJonesRSThe anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitroNeuropharmacology200039112139214610963757
   PubMed Web of Science ®Google Scholar
• BursteinAHLamotriginePharmacotherapy19951521291437624259
   PubMed Web of Science ®Google Scholar
• KetterTAManjiHKPostRMPotential mechanisms of action of lamotrigine in the treatment of bipolar disordersJ Clin Psychopharmacol200323548449514520126
   PubMed Web of Science ®Google Scholar
• BowdenCLCalabreseJRSachsGLamictal 606 Study GroupA placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorderArch Gen Psychiatry200360439240012695317
   PubMed Web of Science ®Google Scholar
• CalabreseJRSuppesTBowdenCLA double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study GroupJ Clin Psychiatry2000611184185011105737
   PubMed Web of Science ®Google Scholar
• ThomasSPNandhraHSJayaramanASystematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)J Ment Health201019216817520433324
   PubMed Web of Science ®Google Scholar
• HertzbergMAButterfieldMIFeldmanMEA preliminary study of lamotrigine for the treatment of posttraumatic stress disorderBiol Psychiatry19994591226122910331117
   PubMed Web of Science ®Google Scholar
• WaldmeierPCBaumannPAWickiPFeldtrauerJJStierlinCSchmutzMSimilar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmittersNeurology19954510190719137477991
   PubMed Web of Science ®Google Scholar
• UzunOLamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case reportJ Psychopharmacol201024342542719010977
   PubMed Web of Science ®Google Scholar
• BrunoAMicòUPandolfoGLamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled studyJ Psychopharmacol201226111456146222351381
   PubMed Web of Science ®Google Scholar
• ErdöSLSchäferMMemantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartateEur J Pharmacol19911982–32152171864308
   PubMed Web of Science ®Google Scholar
• KornhuberJWellerMSchoppmeyerKRiedererPAmantadine and memantine are NMDA receptor antagonists with neuroprotective propertiesJ Neural Transm Suppl199443911047884411
   PubMedGoogle Scholar
• EmreMTsolakiMBonuccelliU11018 Study InvestigatorsMemantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trialLancet Neurol201091096997720729148
   PubMed Web of Science ®Google Scholar
• CankurtaranESOzalpESoygurHCakirAClinical experience with risperidone and memantine in the treatment of Huntington’s diseaseJ Natl Med Assoc20069881353135516916137
   PubMed Web of Science ®Google Scholar
• TariotPNFarlowMRGrossbergGTGrahamSMMcDonaldSGergelIMemantine Study GroupMemantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trialJAMA2004291331732414734594
   PubMed Web of Science ®Google Scholar
• HezelDMBeattieKStewartSEMemantine as an augmenting agent for severe pediatric OCDAm J Psychiatry2009166223719188297
   PubMed Web of Science ®Google Scholar
• PasquiniMBiondiMMemantine augmentation for refractory obsessive-compulsive disorderProg Neuropsychopharmacol Biol Psychiatry20063061173117516730870
   PubMed Web of Science ®Google Scholar
• AboujaoudeEBarryJJGamelNMemantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trialJ Clin Psychopharmacol2009291515519142108
   PubMed Web of Science ®Google Scholar
• FeusnerJDKerwinLSaxenaSBystritskyADifferential efficacy of memantine for obsessive-compulsive disorder vs generalized anxiety disorder: an open-label trialPsychopharmacol Bull2009421819319204653
   PubMed Web of Science ®Google Scholar
• GhaleihaAEntezariNModabberniaAMemantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled studyJ Psychiatr Res201347217518023063327
   PubMed Web of Science ®Google Scholar
• BlumsteinCGDrug treatment in bronchial asthmaSemin Drug Treat1973243854014581867
   PubMedGoogle Scholar
• SteyCSteurerJBachmannSMediciTCTramèrMRThe effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic reviewEur Respir J200016225326210968500
   PubMed Web of Science ®Google Scholar
• SadowskaAMVerbraeckenJDarquennesKDe BackerWARole of N-acetylcysteine in the management of COPDInt J Chron Obstruct Pulmon Dis20061442543418044098
   PubMedGoogle Scholar
• RumackBHAcetaminophen overdose in children and adolescentsPediatr Clin North Am19863336917013714342
   PubMed Web of Science ®Google Scholar
• KearnsGLLeederJSWassermanGSAcetaminophen intoxication during treatment: what you don’t know can hurt youClin Pediatr (Phila)200039313314410752006
   PubMed Web of Science ®Google Scholar
• HeardKGreenJAcetylcysteine therapy for acetaminophen poisoningCurr Pharm Biotechnol201213101917192322352734
   PubMed Web of Science ®Google Scholar
• AricaVDemirİHTutancMN-acetylcysteine prevents doxorubucine-induced cardiotoxicity in ratsHum Exp Toxicol201332665566123424206
   PubMed Web of Science ®Google Scholar
• Soltan-SharifiMSMojtahedzadehMNajafiAImprovement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanismsHum Exp Toxicol200726969770317984140
   PubMed Web of Science ®Google Scholar
• WuYJMuldoonLLNeuweltEAThe chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathwayJ Pharmacol Exp Ther2005312242443115496615
   PubMed Web of Science ®Google Scholar
• OrhanGYapiciNYukselMEffects of N-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgeryHeart Vessels2006211424716440148
   PubMed Web of Science ®Google Scholar
• Borges-SantosMDMoretoFPereiraPCMing-YuYBuriniRCPlasma glutathione of HIV+ patients responded positively and differently to dietary supplementation with cysteine or glutamineNutrition2012287–875375622261571
   PubMed Web of Science ®Google Scholar
• KandemirHAbuhandanMAksoyNSavikEKayaCOxidative imbalance in child and adolescent patients with obsessive compulsive disorderJ Psychiatr Res201347111831183424011862
   PubMed Web of Science ®Google Scholar
• ErsanSBakirSErdal ErsanEDoganOExamination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorderProg Neuropsychopharmacol Biol Psychiatry20063061039104216682105
   PubMed Web of Science ®Google Scholar
• LafleurDLPittengerCKelmendiBN-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorderPsychopharmacology (Berl)2006184225425616374600
   PubMed Web of Science ®Google Scholar
• WikkeJRiluzoleLancet199634890307957998813989
   PubMed Web of Science ®Google Scholar
• JehleTBauerJBlauthEEffects of riluzole on electrically evoked neurotransmitter releaseBr J Pharmacol200013061227123410903959
   PubMed Web of Science ®Google Scholar
• UrbaniABelluzziORiluzole inhibits the persistent sodium current in mammalian CNS neuronsEur J Neurosci200012103567357411029626
   PubMed Web of Science ®Google Scholar
• SreedharanJBrownRHJrAmyotrophic lateral sclerosis: problems and prospectsAnn Neurol201374330931624038380
   PubMed Web of Science ®Google Scholar
• ClarkWKendallMJTherapeutic advances: riluzole for the treatment of motor neurone diseaseJ Clin Pharm Ther19962163733769201563
   PubMed Web of Science ®Google Scholar
• GordonPHAmyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trialsAging Dis20134529531024124634
   PubMed Web of Science ®Google Scholar
• LacomblezLBensimonGLeighPNALS Study Groups I and IILong-term safety of riluzole in amyotrophic lateral sclerosisAmyotroph Lateral Scler Other Motor Neuron Disord200231232912061945
   PubMed Web of Science ®Google Scholar
• CoricVTaskiranSPittengerCRiluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trialBiol Psychiatry200558542442815993857
   PubMed Web of Science ®Google Scholar
• GrantPLougeeLHirschtrittMSwedoSEAn open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorderJ Child Adolesc Psychopharmacol200717676176718315448
   PubMed Web of Science ®Google Scholar
• GrantPJJosephLAFarmerCA12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorderNeuropsychopharmacology20143961453145924356715
   PubMed Web of Science ®Google Scholar
• GarnettWRClinical pharmacology of topiramate: a reviewEpilepsia200041Suppl 1S61S6510768303
   PubMed Web of Science ®Google Scholar
• BauerJSchwalenSTopiramate (Topamax). Pharmacological characteristics and current use in epilepsy treatmentNervenarzt2000716495501 German10919147
   PubMed Web of Science ®Google Scholar
• PoulsenCFSimeoneTAMaarTESmith-SwintoskyVWhiteHSSchousboeAModulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neuronsNeurochem Res200429127528214992287
   PubMed Web of Science ®Google Scholar
• ManningSPucciAFinerNPharmacotherapy for obesity: novel agents and paradigmsTher Adv Chronic Dis20145313514824790728
   PubMedGoogle Scholar
• LindeMMullenersWMChronicleEPMcCroryDCTopiramate for the prophylaxis of episodic migraine in adultsCochrane Database Syst Rev20136CD01061023797676
   PubMed Web of Science ®Google Scholar
• HollanderEDell’OssoBTopiramate plus paroxetine in treatment-resistant obsessive-compulsive disorderInt Clin Psychopharmacol200621318919116528143
   PubMed Web of Science ®Google Scholar
• Van AmeringenMManciniCPattersonBBennettMTopiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case seriesDepress Anxiety20062311516178009
   PubMed Web of Science ®Google Scholar
• BerlinHAKoranLMJenikeMADouble-blind, placebo- controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorderJ Clin Psychiatry201172571672120816027
   PubMed Web of Science ®Google Scholar
• OzkaraCOzmenMErdoganAYalugITopiramate related obsessive-compulsive disorderEur Psychiatry2005201787915642451
   PubMed Web of Science ®Google Scholar
• Lauria-HornerBAPohlRBPregabalin: a new anxiolyticExpert Opin Investig Drugs2003124663672
   PubMed Web of Science ®Google Scholar
• MichevaKDTaylorCPSmithSJPregabalin reduces the release of synaptic vesicles from cultured hippocampal neuronsMol Pharmacol200670246747616641316
   PubMed Web of Science ®Google Scholar
• OulisPMourikisIKonstantakopoulosGPregabalin augmentation in treatment-resistant obsessive-compulsive disorderInt Clin Psychopharmacol201126422122421460732
   PubMed Web of Science ®Google Scholar
• RampelloLAlvanoABattagliaGBrunoVRaffaeleRNicolettiFTic disorders: from pathophysiology to treatmentJ Neurol2006253111516331353
   PubMed Web of Science ®Google Scholar
• SpechtMWNicotraCMKellyLMA Comparison of urge intensity and the probability of tic completion during tic freely and tic suppression conditionsBehav Modif201438229731824924158
   PubMed Web of Science ®Google Scholar
• WoodsDWPiacentiniJCScahillLBehavior therapy for tics in children: acute and long-term effects on psychiatric and psychosocial functioningJ Child Neurol201126785886521555779
   PubMed Web of Science ®Google Scholar
• WilhelmSPetersonALPiacentiniJRandomized trial of behavior therapy for adults with Tourette syndromeArch Gen Psychiatry201269879580322868933
   PubMed Web of Science ®Google Scholar
• RizzoRGulisanoMClinical pharmacology of comorbid attention deficit hyperactivity disorder in Tourette syndromeInt Rev Neurobiol201311241544424295629
   PubMed Web of Science ®Google Scholar
• NeriVCardonaFClinical pharmacology of comorbid obsessive-compulsive disorder in Tourette syndromeInt Rev Neurobiol201311239141424295628
   PubMed Web of Science ®Google Scholar
• RizzoRGulisanoMPellicoACalìPVCuratoloPTourette syndrome and comorbid conditions: a spectrum of different severities and complexitiesJ Child Neurol201429101383138924832397
   PubMed Web of Science ®Google Scholar
• BerardelliACurràAFabbriniGGilioFManfrediMPathophysiology of tics and Tourette syndromeJ Neurol2003250778178712883917
   PubMed Web of Science ®Google Scholar
• SingerHSMinzerKNeurobiology of Tourette’s syndrome: concepts of neuroanatomic localization and neurochemical abnormalitiesBrain Dev200325Suppl 1S70S8414980376
   PubMed Web of Science ®Google Scholar
• NomuraYSegawaMNeurology of Tourette’s syndrome (TS) TS as a developmental dopamine disorder: a hypothesisBrain Dev200325Suppl 1S37S4214980371
   PubMed Web of Science ®Google Scholar
• YoonDYGauseCDLeckmanJFSingerHSFrontal dopaminergic abnormality in Tourette syndrome: a postmortem analysisJ Neurol Sci20072551–2505617337006
   PubMed Web of Science ®Google Scholar
• UdvardiPTNespoliERizzoFHengererBLudolphAGNondopaminergic neurotransmission in the pathophysiology of Tourette syndromeInt Rev Neurobiol20131129513024295619
   PubMed Web of Science ®Google Scholar
• SingerHSMorrisCGradosMGlutamatergic modulatory therapy for Tourette syndromeMed Hypotheses201074586286720022434
   PubMed Web of Science ®Google Scholar
• AndersonGMPollakESChatterjeeDLeckmanJFRiddleMACohenDJPostmortem analysis of subcortical monoamines and amino acids in Tourette syndromeAdv Neurol1992581231331414615
   PubMedGoogle Scholar
• SwerdlowNRSutherlandANUsing animal models to develop therapeutics for Tourette SyndromePharmacol Ther2005108328129315970330
   PubMed Web of Science ®Google Scholar
• McGrathMJCampbellKMParksCRBurtonFHGlutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette’s syndrome and obsessive-compulsive disorderBrain Res20008771233010980239
   PubMed Web of Science ®Google Scholar
• NordstromEJBurtonFHA transgenic model of comorbid Tourette’s syndrome and obsessive-compulsive disorder circuitryMol Psychiatry20027661762552412140785
   PubMed Web of Science ®Google Scholar
• ShoemakerJMSaint MarieRLBongiovanniMJNearyACTochenLSSwerdlowNRPrefrontal D1 and ventral hippocampal N-methyl-D-aspartate regulation of startle gating in ratsNeuroscience2005135238539416125865
   PubMed Web of Science ®Google Scholar
• AbelKMAllinMPHemsleyDRGeyerMALow dose ketamine increases prepulse inhibition in healthy menNeuropharmacology200344672973712681371
   PubMed Web of Science ®Google Scholar
• DuncanEJMadonickSHParwaniAClinical and sensorimotor gating effects of ketamine in normalsNeuropsychopharmacology2001251728311377920
   PubMed Web of Science ®Google Scholar
• OrtizAAldaMO’DonovanCTourette syndrome with comorbid bipolar disorder and migraine: can lamotrigine monotherapy help?J Clin Psychopharmacol201232114014222217952
   PubMed Web of Science ®Google Scholar
• SeemüllerFDehningSGrunzeHMüllerNTourette’s symptoms provoked by lamotrigine in a bipolar patientAm J Psychiatry2006163115916390908
   PubMed Web of Science ®Google Scholar
• LombrosoCTLamotrigine-induced tourettismNeurology19995261191119410214742
   PubMed Web of Science ®Google Scholar
• Sotero de MenezesMARhoJMMurphyPCheyetteSLamotrigine-induced tic disorder: report of five pediatric casesEpilepsia200041786286710897158
   PubMed Web of Science ®Google Scholar
• RobertsonMMEapenVCavannaAEThe international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspectiveJ Psychosom Res200967647548319913651
   PubMed Web of Science ®Google Scholar
• FornaroMMaremmaniAGColicchioMGA case of severe oral self-injurious Tourette’s syndrome alleviated by pregabalinGen Hosp Psychiatry2012343321.e1e422133981
   PubMedGoogle Scholar
• KuoSHJimenez-ShahedJTopiramate in treatment of tourette syndromeClin Neuropharmacol2010331323419935407
   PubMed Web of Science ®Google Scholar
• JankovicJJimenez-ShahedJBrownLWA randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndromeJ Neurol Neurosurg Psychiatry2010811707319726418
   PubMed Web of Science ®Google Scholar
• UnderhillSMWheelerDSLiMWattsSDIngramSLAmaraSGAmphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neuronsNeuron201483240441625033183
   PubMed Web of Science ®Google Scholar
• RollandBJardriRAmadAThomasPCottencinOBordetRPharmacology of hallucinations: several mechanisms for one single symptom?Biomed Res Int2014201430710624991548
   PubMed Web of Science ®Google Scholar
• TaylorMBhagwandasKN-acetylcysteine in trichotillomania: a panacea for compulsive skin disorders?Br J Dermatol201417151253125524773206
   PubMed Web of Science ®Google Scholar
• Van AmeringenMPattersonBSimpsonWDSM-5 obsessive-compulsive and related disorders: clinical implications of new criteriaDepress Anxiety201431648749324616177
   PubMed Web of Science ®Google Scholar
• MasurDShinnarSCnaanAChildhood Absence Epilepsy Study GroupPretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsyNeurology201381181572158024089388
   PubMed Web of Science ®Google Scholar
• MalloMAlonsoCRThe regulation of Hox gene expression during animal developmentDevelopment2013140193951396324046316
   PubMed Web of Science ®Google Scholar
• PanzaKEPittengerCBlochMHAge and gender correlates of pulling in pediatric trichotillomaniaJ Am Acad Child Adolesc Psychiatry201352324124923452681
   PubMed Web of Science ®Google Scholar
• BlochMHPanzaKEGrantJEPittengerCLeckmanJFN-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trialJ Am Acad Child Adolesc Psychiatry201352323124023452680
   PubMed Web of Science ®Google Scholar
• Rodrigues-BarataARTostiARodríguez-PichardoACamacho-MartínezFN-acetylcysteine in the treatment of trichotillomaniaInt J Trichology20124317617823180931
   PubMedGoogle Scholar
• GrantJEOdlaugBLChamberlainSRKeuthenNJLochnerCSteinDJSkin picking disorderAm J Psychiatry2012169111143114923128921
   PubMed Web of Science ®Google Scholar
• Schneebaum-SenderNGoldberg-SternHFattal-ValevskiAKramerUDoes a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder?Pediatr Neurol201247427928322964442
   PubMed Web of Science ®Google Scholar
• WuJXiaoHSunHZouLZhuLQRole of dopamine receptors in ADHD: a systematic meta-analysisMol Neurobiol201245360562022610946
   PubMed Web of Science ®Google Scholar
• GrantJEOdlaugBLChamberlainSRA cognitive comparison of pathological skin picking and trichotillomaniaJ Psychiatr Res201145121634163821824627
   PubMed Web of Science ®Google Scholar
• ChamberlainSRHampshireAMenziesLAReduced brain white matter integrity in trichotillomania: a diffusion tensor imaging studyArch Gen Psychiatry201067996597120819990
   PubMed Web of Science ®Google Scholar
• GrantJEOdlaugBLChamberlainSRKimSWA double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of responseJ Clin Psychopharmacol201030439640320531220
   PubMed Web of Science ®Google Scholar
• GrantJEOdlaugBLKimSWN-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled studyArch Gen Psychiatry200966775676319581567
   PubMed Web of Science ®Google Scholar
• ChamberlainSROdlaugBLBoulougourisVFinebergNAGrantJETrichotillomania: neurobiology and treatmentNeurosci Biobehav Rev200933683184219428495
   PubMed Web of Science ®Google Scholar
• PaineTANeveRLCarlezonWAJrAttention deficits and hyperactivity following inhibition of cAMP-dependent protein kinase within the medial prefrontal cortex of ratsNeuropsychopharmacology20093492143215519387423
   PubMed Web of Science ®Google Scholar
• TsengKYO’DonnellPDopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanismsJ Neurosci200424225131513915175382
   PubMed Web of Science ®Google Scholar
• MacMasterFPCarreyNSparkesSKusumakarVProton spectroscopy in medication-free pediatric attention-deficit/hyperactivity disorderBiol Psychiatry200353218418712547476
   PubMed Web of Science ®Google Scholar
• CarreyNMacMasterFPFogelJMetabolite changes resulting from treatment in children with ADHD: a 1H-MRS studyClin Neuropharmacol200226421822112897644
   PubMed Web of Science ®Google Scholar
• CarreyNMacMasterFPSparkesSJKhanSCKusumakarVGlutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case seriesJ Child Adolesc Psychopharmacol200212433133612625993
   PubMed Web of Science ®Google Scholar
• BushGLuuPPosnerMICognitive and emotional influences in anterior cingulate cortexTrends Cogn Sci20004621522210827444
   PubMed Web of Science ®Google Scholar
• HammernessPBiedermanJPettyCHeninAMooreCMBrain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot studyCNS Neurosci Ther2012181344021143432
   PubMed Web of Science ®Google Scholar
• XuMMoratallaRGoldLHDopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responsesCell19947947297427954836
   PubMed Web of Science ®Google Scholar
• GranonSPassettiFThomasKLDalleyJWEverittBJRobbinsTWEnhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortexJ Neurosci20002031208121510648725
   PubMed Web of Science ®Google Scholar
• WartonFLHowellsFMRussellVAIncreased glutamate-stimulated release of dopamine in substantia nigra of a rat model for attention-deficit/hyperactivity disorder – lack of effect of methylphenidateMetab Brain Dis200924459961319821016
   PubMed Web of Science ®Google Scholar
• MillerJLAnguloMAn open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndromeAm J Med Genet A2014164A242142424311388
   PubMed Web of Science ®Google Scholar
• LeschKPMerkerSReifANovakMDances with black widow spiders: dysregulation of glutamate signalling enters centre stage in ADHDEur Neuropsychopharmacol201323647949122939004
   PubMed Web of Science ®Google Scholar
• EliaJGlessnerJTWangKGenome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorderNat Genet2012441788422138692
   PubMed Web of Science ®Google Scholar
• RubinsteinMCepedaCHurstRSDopamine D4 receptor-deficient mice display cortical hyperexcitabilityJ Neurosci200121113756376311356863
   PubMed Web of Science ®Google Scholar
• WangXZhongPGuZYanZRegulation of NMDA receptors by dopamine D4 signaling in prefrontal cortexJ Neurosci200323309852986114586014
   PubMed Web of Science ®Google Scholar
• GanLFalzoneTLZhangKRubinsteinMBaldessariniRJTaraziFIEnhanced expression of dopamine D(1) and glutamate NMDA receptors in dopamine D(4) receptor knockout miceJ Mol Neurosci200422316717814997010
   PubMed Web of Science ®Google Scholar
• ThomasTCGrandyDKGerhardtGAGlaserPEDecreased dopamine D4 receptor expression increases extracellular glutamate and alters its regulation in mouse striatumNeuropsychopharmacology200934243644518536704
   PubMed Web of Science ®Google Scholar
• ShaywitzAJGreenbergMECREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signalsAnnu Rev Biochem19996882186110872467
   PubMed Web of Science ®Google Scholar
• PozziLBavieraMSacchettiGAttention deficit induced by blockade of N-methyl D-aspartate receptors in the prefrontal cortex is associated with enhanced glutamate release and cAMP response element binding protein phosphorylation: role of metabotropic glutamate receptors 2/3Neuroscience201117633634821193020
   PubMed Web of Science ®Google Scholar
• ViggianoDValloneDWelzlHSadileAGThe Naples High- and Low-Excitability rats: selective breeding, behavioral profile, morphometry, and molecular biology of the mesocortical dopamine systemBehav Genet200232531533312405514
   PubMed Web of Science ®Google Scholar
• RuoccoLAGironi CarnevaleUASadileAGElevated forebrain excitatory L-glutamate, L-aspartate and D-aspartate in the Naples high-excitability ratsBehav Brain Res20091981242819073221
   PubMed Web of Science ®Google Scholar
• MattesJA pilot trial of amantadine in hyperactive childrenPsychopharmacol Bull198016367697403410
   PubMedGoogle Scholar
• DonfrancescoRCalderoniDVitielloBOpen-label amantadine in children with attention-deficit/hyperactivity disorderJ Child Adolesc Psychopharmacol200717565766417979585
   PubMed Web of Science ®Google Scholar
• MohammadiMRKazemiMRZiaERezazadehSATabriziMAkhondzadehSAmantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trialHum Psychopharmacol2010257–856056521312290
   PubMed Web of Science ®Google Scholar
• ÖncüBErOÇolakBNuttDJLamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case seriesJ Psychopharmacol201428328228323784736
   PubMed Web of Science ®Google Scholar
• UvebrantPBauzienèRIntractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefitsNeuropediatrics19942562842897770124
   PubMed Web of Science ®Google Scholar
• SchubertRAttention deficit disorder and epilepsyPediatr Neurol200532111015607597
   PubMed Web of Science ®Google Scholar
• PeetersMMaloteauxJMHermansEDistinct effects of amantadine and memantine on dopaminergic transmission in the rat striatumNeurosci Lett2003343320520912770697
   PubMed Web of Science ®Google Scholar
• FindlingRLMcNamaraNKStansbreyRJA pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined typeJ Child Adolesc Psychopharmacol2007171193317343551
   PubMed Web of Science ®Google Scholar
• SurmanCBHammernessPGPettyCA pilot open label prospective study of memantine monotherapy in adults with ADHDWorld J Biol Psychiatry201314429129822436083
   PubMed Web of Science ®Google Scholar
• GarciaRJFrancisLDawoodMLaiZWFaraoneSVPerlAAttention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosusArthritis Rheum20136551313131823400548
   PubMed Web of Science ®Google Scholar
• ArnoldLMAuchenbachMBMcElroySLPsychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatmentCNS Drugs200115535135911475941
   PubMed Web of Science ®Google Scholar
• KeuthenNJKoranLMAboujaoudeELargeMDSerpeRTThe prevalence of pathologic skin picking in US adultsCompr Psychiatry201051218318620152300
   PubMed Web of Science ®Google Scholar
• HayesSLStorchEABerlangaLSkin picking behaviors: An examination of the prevalence and severity in a community sampleJ Anxiety Disord200923331431919223150
   PubMed Web of Science ®Google Scholar
• SwedoSERapoportJLAnnotation: trichotillomaniaJ Child Psychol Psychiatry19913234014092061361
   PubMed Web of Science ®Google Scholar
• NezirogluFRabinowitzDBreytmanAJacofskyMSkin picking phenomenology and severity comparisonPrim Care Companion J Clin Psychiatry200810430631218787665
   PubMedGoogle Scholar
• BohneASavageCRDeckersbachTKeuthenNJWilhelmSMotor inhibition in trichotillomania and obsessive-compulsive disorderJ Psychiatr Res200842214115017215004
   PubMed Web of Science ®Google Scholar
• SwedoSERapoportJLLeonardHLSchapiroMBRapoportSIGradyCLRegional cerebral glucose metabolism of women with trichotillomaniaArch Gen Psychiatry19914898288331929773
   PubMed Web of Science ®Google Scholar
• RoosAFoucheJPSteinDJLochnerCWhite matter integrity in hair-pulling disorder (trichotillomania)Psychiatry Res2013211324625023149033
   PubMed Web of Science ®Google Scholar
• GrantJEOdlaugBLHampshireASchreiberLRChamberlainSRWhite matter abnormalities in skin picking disorder: a diffusion tensor imaging studyNeuropsychopharmacology201338576376923303052
   PubMed Web of Science ®Google Scholar
• StratfordTHKostakopoulouKMadenMHoxb-8 has a role in establishing early anterior-posterior polarity in chick forelimb but not hindlimbDevelopment199712421422542349334271
   PubMed Web of Science ®Google Scholar
• GreerJMCapecchiMRHoxb8 is required for normal grooming behavior in miceNeuron2002331233411779477
   PubMed Web of Science ®Google Scholar
• WelchJMWangDFengGDifferential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouseJ Comp Neurol20044721243915024750
   PubMed Web of Science ®Google Scholar
• BienvenuOJWangYShugartYYSapap3 and pathological grooming in humans: Results from the OCD collaborative genetics studyAm J Med Genet B Neuropsychiatr Genet2009150B571072019051237
   PubMed Web of Science ®Google Scholar
• ZüchnerSWendlandJRAshley-KochAEMultiple rare SAPAP3 missense variants in trichotillomania and OCDMol Psychiatry20091416919096451
   PubMed Web of Science ®Google Scholar
• OdlaugBLGrantJEN-acetyl cysteine in the treatment of grooming disordersJ Clin Psychopharmacol200727222722917414258
   PubMed Web of Science ®Google Scholar
• GrantJEOdlaugBLKimSWLamotrigine treatment of pathologic skin picking: an open-label studyJ Clin Psychiatry20076891384139117915977
   PubMed Web of Science ®Google Scholar
• LochnerCSeedatSNiehausDJSteinDJTopiramate in the treatment of trichotillomania: an open-label pilot studyInt Clin Psychopharmacol200621525525916877895
   PubMed Web of Science ®Google Scholar
• ShapiraNALessigMCMurphyTKDriscollDJGoodmanWKTopiramate attenuates self-injurious behaviour in Prader-Willi SyndromeInt J Neuropsychopharmacol20025214114512135538
   PubMed Web of Science ®Google Scholar
• JafferanyMShireenFIbrahimAAn open-label trial of topiramate in the treatment of skin picking in pervasive developmental disorder not otherwise specifiedPrim Care Companion J Clin Psychiatry2010122piiPCC.09l00829
   Google Scholar
• CoricVKelmendiBPittengerCWasylinkSBlochMHGreenJBeneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomaniaJ Clin Psychiatry200768117017117284151
   PubMed Web of Science ®Google Scholar
• RothmanSMMattsonMPActivity-dependent, stress-responsive BDNF signaling and the quest for optimal brain health and resilience throughout the lifespanNeuroscience201323922824023079624
   PubMed Web of Science ®Google Scholar
• TanakaKBrain development and glutamateBrain Nerve2013651011211132 Japanese24101424
   PubMedGoogle Scholar
• NakamichiNTakaradaTYonedaYNeurogenesis mediated by gamma-aminobutyric acid and glutamate signalingJ Pharmacol Sci2009110213314919483378
   PubMed Web of Science ®Google Scholar
• MattsonMPGlutamate and neurotrophic factors in neuronal plasticity and diseaseAnn N Y Acad Sci200811449711219076369
   PubMed Web of Science ®Google Scholar